(Z)-2-(5-benzylidene-4-oxo-2-thioxothiazolidin-3-yl)-3-methylbutanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Z)-2-(5-benzylidene-4-oxo-2-thioxothiazolidin-3-yl)-3-methylbutanoic acid
• 英文别名: 2-[(5Z)-5-benzylidene-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-methylbutanoic acid
• 化学式: C₁₅H₁₅NO₃S₂
• 分子量: 321.4
• InChiKey: JZLLRVWRJBPACN-FLIBITNWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Method for producing hypertrophic scarring animal model for identification of agents for prevention and treatment of human hypertrophic scarring
  申请人：Gurtner C. Geoffrey

  公开号：US20060037091A1

  公开（公告）日：2006-02-16

  The present invention relates to a method of producing a non-human animal model of hypertrophic scarring. This involves producing an incision in a non-human animal and applying mechanical strain over the incision under conditions effective to produce hypertrophic scarring, thereby producing a non-human animal model of hypertrophic scarring. The present invention also relates to a method of determining the efficacy of an agent for prevention or treatment of a disease condition. This method involves providing a non-human animal having an incision over which mechanical strain is applied under conditions effective to produce hypertrophic scarring, administering an agent to the incision, and determining whether the agent is efficacious for prevention or treatment of a disease condition. Also provided is a non-human animal model of hypertrophic scarring. This involves a non-human animal having an incision over which mechanical strain has been applied under conditions effective to produce hypertrophic scarring.

  本发明涉及一种制作非人类动物增生性瘢痕模型的方法。这包括在非人类动物身上制作切口，并在有效产生增生性瘢痕的条件下对切口施加机械应变，从而制作出增生性瘢痕的非人类动物模型。本发明还涉及一种确定预防或治疗疾病药剂疗效的方法。该方法包括提供一种非人类动物，该动物有一个切口，在有效产生增生性瘢痕的条件下，在该切口上施加机械应变，在该切口上施用一种药剂，并确定该药剂是否具有预防或治疗疾病的功效。此外，还提供了一种增生性瘢痕的非人类动物模型。这涉及到非人类动物的切口，在有效产生增生性瘢痕的条件下，在切口上施加机械应变。
• USE OF BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTITUMOR DRUG
  申请人：GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.

  公开号：US20190183948A1

  公开（公告）日：2019-06-20

  This invention belongs to the field of biomedicine and relates to use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that the Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. The present invention also relates to a pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors, especially, tumors that are not sensitive to the oncolytic virus.